Article Text
Abstract
The approach to metastatic lung cancer has long been focused on palliation therapy and comfort care. Recently, significant subsets of patients who suffer from a limited form of the disease have shown curative outcomes. The oligometastatic disease theory was first introduced in 1995, and since has been applied to many solid tumours. In oligometastatic nonsmall cell lung cancer, current treatment strategies include surgery, radiation therapy and chemotherapy. There is evidence of astounding survival benefits in selected patients treated with immune checkpoint inhibitors. We present three cases with oligometastatic nonsmall cell lung cancer treated with pembrolizumab, an immune checkpoint inhibitor, and describe the outcomes. Immunotherapy with pembrolizumab appears to be an effective adjunctive treatment with low toxicity in oligometastatic nonsmall cell lung cancer.
- cancer intervention
- malignant disease and immunosuppression
- neuroimaging
- radiotherapy
- respiratory cancer
Statistics from Altmetric.com
Footnotes
Contributors Study Design (A) Data Collection (B) Statistical Analysis (C) Data Interpretation(D) Manuscript Preparation (E) Literature Search (F) Funds Collection (G) YG (A,B,E,F)AE-F (B,F)JT(A,D,E)SC (E,F)
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.